Lundbeck forms strategic alliance to market Lexapro and Cipramil in China  

Lundbeck strikes a deal with Janssen-Cilag to market its antidepressants in over 200 Chinese cities

Danish pharmaceutical company H. Lundbeck has entered an agreement with Switzerland's Janssen-Cilag International to market, sell and distribute Lexapro (escitalopram) and Cipramil (citalopram) in China through Xian-Janssen Pharmaceutical Ltd, Beijing. The antidepressants will be promoted by Xian-Janssen medical representatives in more than 200 cities and over 2,000 hospitals nationwide. The news is reported on Lundbeck's website.


Lexapro is a Lundbeck's second-generation selective serotonin reuptake inhibitor (SSRI) for the treatment of depression and panic disorders. Clinical trials have shown the drug to be effective and well tolerated, providing symptom relief as early as the first week. Over the next 5 years, Lundbeck is reportedly investing more than DKK 1 billion (USD 130 million) each year to globally market Lexapro. The company recently struck a deal with Abbott Laboratories to market, sell and distribute Lexapro in all Latin American markets.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×